Navigation Links
Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
Date:10/13/2010

NEW YORK, Oct. 13 /PRNewswire/ -- Following recent FDA approvals for prostate cancer treatment medications from Dendreon and Sanofi-Aventis, a new study shows that the lives of men with advanced prostate cancer were prolonged almost four months on Abiraterone, a new medication from Johnson & Johnson. The drug, which could reach the market in 2011, is positive prostate cancer treatment news with the potential to change clinical practice by providing a new treatment option for aggressive prostate cancer. Dr. David Samadi, a robotic surgery expert who is the Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City, described the study, which was presented at the European Society for Medical Oncology (ESMO) congress, "As yet another in a series of successful scientific steps towards fighting prostate cancer, a common, and sometimes deadly enemy."

(Logo: http://photos.prnewswire.com/prnh/20101013/NY81775LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101013/NY81775LOGO)

The study followed over 1,000 men with aggressive prostate cancer and poor prognoses, who had only been given months left to live. In this group, 797 were prescribed abiraterone acetate as well as prednisone, a steroid, while the rest were given prednisone and a placebo treatment for prostate cancer. Abiraterone, discovered by Britain's Institute of Cancer Research, blocks the production of hormones that stimulate prostate cancer tumors. Abiraterone's side effects include fluid retention and hypokalemia (low levels of potassium in the blood).

The study showed that Johnson & Johnson's experimental drug not only delayed prostate cancer growth but also significantly increased the patients' life expectancy by 36%, from 10.9 to 14.8 months. The risk of death among patients on the drug also dropped by 35%. "Sure, 3.9 months does not sound like a lot of time, but in terms of the scientific history of prostate cancer, previously only four drugs had ever proven a survival potential," said Dr. Samadi, a robotic prostatectomy expert as well as a urologic oncologist with Mt. Sinai, "The discovery of this drug is even more significant because patients with the aggressive type of this disease have very limited prostate cancer treatment options and usually a terminal prognosis."

Analysts compared abiraterone to Dendreon's vaccine, Provenge, as "a nearly billion dollar opportunity" for Johnson & Johnson and "more compelling" than Sanofi-Aventis' chemotherapy, Jevtana. The latter had been approved this past June for advanced prostate cancer treatment after a study showed prolonged survival of 2.4 months. The FDA approved Provenge in April of this year for treating prostate cancer. However, sales have been impacted by limited production, which should be resolved by mid-2011. Critics says Provenge's hefty $93,000 price tag for three treatments is another sales hurdle though the company claims the price is comparable to other available treatments.

"It's been a landmark year for prostate cancer news, where we are hopefully moving towards making prostate cancer a treatable disease that the patient can survive with a specific drug treatment plan," said Dr. Samadi, "In fact, these drugs may not even be rivals, but viable prostate cancer treatment options that can be administered in a series to battle this disease."


'/>"/>
SOURCE RoboticOncology.com
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Robotics Expands Operations Into Bosnia, Croatia, Finland, Macedonia, Montenegro, Serbia, and Slovenia
2. 100,000th Patient Treated With Accurays CyberKnife® Robotic Radiosurgery System
3. With Over 3,000 Robotic Prostatectomy Surgeries to His Credit, Dr. David Samadi, MD Discusses SMART Surgery and How it Improves Sexual and Urinary Function
4. International Robotic Urology Symposium 2011
5. Health Robotics Continues Worldwide Distribution Channel Expansion in Bulgaria, Czech Republic, Romania and Slovakia
6. Robotic Prostatectomy Expert Dr. David Samadi, MD Introduces His SMART Surgery Website for Prostate Cancer Treatment Education
7. Robotic Prostatectomy Expert Dr. David Samadi, MD Talks About Prostate Cancer Treatment News and Developments
8. Robotic Surgery Expert Dr. David B. Samadi, MD Discusses New Evidence That Proves The Low Complication Rates of Robotic Prostatectomy
9. Health Robotics Continues to Dominate I.V. Automation in America, With 11 New Contracts in Second Quarter 2010
10. Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies
11. RoboticOncology.com: Robotic Surgeon Dr. David Samadi, MD Introduces His SMART Surgery Technique for Prostate Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... individuals with HIV because it is not known to have significant interactions with ... effects to both lower cholesterol levels and dampen inflammation in the bloodstream. , ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Reflections of God’s Work”: ... “Reflections of God’s Work” is the creation of published author, Jerri Broglin, a survivor ... , “I believe this a great eye-opener for those searching for answers, as ...
(Date:4/24/2017)... ... April 24, 2017 , ... Miami Periodontist ... 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held ... its annual Global Symposium at the Fontainebleau Hotel located in Miami Beach, FL. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda ... generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announced ... device as the product advances towards regulatory and clinical phases. , "This is ...
Breaking Medicine News(10 mins):